We are a group of patients dedicated to improving outcomes for people living with PIK3CA altered breast cancer.
PIK3CA is the most frequently altered gene in breast cancer. However, gaps in diagnostics, therapeutics, side effects, clinical trials, and real world data prevent us from optimizing care.
Our mission is to improve outcomes by providing multidirectional education, raising awareness around PIK3CA as a biomarker, and accelerating translational and real world research.
We are just getting started.
We are officially launching at the San Antonio Breast Cancer Symposium 2023. We have several concrete goals for our first year to be accomplished by dedicated working groups:
Develop patient-centered educational materials with a focus on genetic sequencing, drugs, and side effects.
Create a curated clinical trials portal of PI3K pathway inhibitors currently being tested all over the world.
Raise funding for translational, clinical, and real world research on PIK3CA.
Organize an annual PIK3CA symposium to connect our community at large.
We are dedicated to engaging with diverse groups of stakeholders.
We seek to connect with patients, advocates, caregivers, oncologists, nurses, pharmacists, and representatives from industry and regulatory bodies.
If you would like to join us —- receive our newsletter, volunteer for our group, take on a leadership role, or interface with our leaders —- please sign up here.
PI3K past, present, and future
Presentation at SABCS 2023, Neil Vasan, MD, PhD